Tag
The 2026 EAPCI–ACVC consensus refines use of temporary mechanical circulatory support in acute myocardial infarction with cardiogenic shock, emphasizing phenotype-driven device selection, SCAI/SHARC staging, multidisciplinary shock teams an
Higher cumulative inotropic exposure during VA ECMO support in cardiogenic shock is associated with increased risk of ECMO weaning failure, mortality, arrhythmias, and delayed lactate clearance, highlighting the need for prospective trials
This review synthesizes evidence on the derivation and validation of a claims-based algorithm for identifying cardiogenic shock (CS), demonstrating its high diagnostic performance and enabling robust large-scale epidemiologic and long-term
Higher hospital cardiac capability correlates with lower mortality in cardiogenic shock patients, and regionalized hub-and-spoke models mitigate the transfer penalty associated with patient instability.
Longer hospital arrival times significantly increase both in-hospital and long-term mortality in cardiogenic shock, highlighting the urgent need for regional care coordination and early triage.
A nationwide South Korean study reveals that longer hospital arrival times significantly increase both in-hospital and long-term mortality in patients with cardiogenic shock, emphasizing the need for improved regional healthcare coordinatio
A large CCCTN analysis found major institutional and patient-level variation in vasoactive drug selection for cardiogenic shock, highlighting persistent evidence gaps in choosing dobutamine, milrinone, and other vasoactive therapies.
A multi-center study reveals that circulatory support escalation in cardiogenic shock is associated with higher mortality and complications, but certain patient factors can predict successful outcomes.
A large observational study reveals that cardiogenic shock patients receiving temporary mechanical circulatory support at regional referral centers before transfer to hub centers experience significantly higher device-related adverse events
This clinical analysis of 500 patients identifies heart failure and arrhythmias as the primary causes of SCAI Stage B shock. Key findings highlight acute kidney injury and diuretic resistance as significant predictors of clinical deteriorat
A large-scale study reveals that 25% of patients with SCAI Stage B cardiogenic shock deteriorate clinically. Acute kidney injury and diuretic resistance are identified as critical, independent predictors of poor outcomes, emphasizing the ne
New research highlights that nearly a quarter of SCAI Stage B cardiogenic shock patients deteriorate. Acute kidney injury and diuretic resistance serve as critical early warning signs, providing clinicians a window for proactive interventio
A large-scale proteomic analysis identifies VEGFR1 as a significant, independent predictor of 180-day mortality in patients with cardiogenic shock, offering incremental prognostic value beyond traditional markers like serum lactate and SAPS
This study validates the DanGer Shock trial criteria in a real-world registry, demonstrating that patients matching the trial’s profile have significantly better survival outcomes when treated with microaxial flow pumps compared to th
Recent substudies from the DanGer Shock trial demonstrate that microaxial flow pumps significantly improve hemodynamics, accelerate lactate clearance, and reduce vasopressor needs in STEMI-related cardiogenic shock, though sex-specific outc
This article analyzes recent J-PVAD registry data, evaluating the real-world applicability of the DanGer shock trial criteria and prognostic factors for ECPELLA in acute myocardial infarction-related cardiogenic shock, emphasizing the neces
A pilot multicenter RCT comparing conservative vs liberal post-oxygenator oxygen targets during VA-ECMO for cardiogenic shock found the conservative approach difficult to maintain (target achieved 33% of time) and no difference in biomarker
A mediation analysis of the randomized ECLS‑SHOCK trial found that VA‑ECMO increased moderate–severe bleeding and vascular complications but these events did not statistically mediate 30‑day mortality in patients with acute myocardial infar
In the LEVOECMO randomized trial (n=205), early levosimendan did not reduce time to successful VA‑ECMO weaning or improve 60‑day mortality versus placebo; ventricular arrhythmias were more frequent with levosimendan.
This post hoc analysis of the DanGer Shock trial reveals that low systolic blood pressure at treatment initiation markedly enhances survival benefit from microaxial flow pump support in infarct-related cardiogenic shock.
